Scaling the ESMO23 ramparts
Scaling the ramparts in Real Madrido
In our last ESMO23 Preview ahead of the live meeting starting on Friday, we highlight another eight targets to watch out for where there will be intriguing data dropping out from Madrid over the weekend.
More than just the data though, is consideration for the implications of the findings and how they can impact a particular tumour landscape.
One thing to note is just because a company highlights what they consider to be positive data doesn’t always mean it is actually so when you look carefully at the small print.
Not surprisingly there are a few examples of this genre at the forthcoming conference…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
